Insmed is a global biopharmaceutical company developing and commercializing therapies for serious diseases across three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. Its two commercial products are ARIKAYCE (amikacin liposome inhalation suspension) for MAC lung disease, approved in the US, EU, and Japan, and BRINSUPRI (brensocatib tablets) for non-cystic fibrosis bronchiectasis, approved in the US and EU in 2025. Its pipeline includes TPIP, INS1148, and gene therapies INS1201 and INS1202.
Q2 FY2026 — expected 2026-08-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001104506-26-000009 | EDGAR | 91K words |
| 2025-02-20 | 2024-12-31 | 0001104506-25-000009 | EDGAR | 90K words |
| 2024-02-22 | 2023-12-31 | 0001104506-24-000008 | EDGAR | 88K words |
| 2023-02-23 | 2022-12-31 | 0001104506-23-000009 | EDGAR | 88K words |
| 2022-02-17 | 2021-12-31 | 0001104506-22-000008 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001104506-21-000005 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001104506-20-000007 | EDGAR | — |
| 2019-02-22 | 2018-12-31 | 0001104506-19-000009 | EDGAR | — |
| 2018-02-23 | 2017-12-31 | 0001104506-18-000002 | EDGAR | — |
| 2017-02-23 | 2016-12-31 | 0001047469-17-000856 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001104506-26-000041 | EDGAR | 22K words |
| 2026-05-07 | 2026-03-31 | 0001104506-26-000032 | EDGAR | 25K words |
| 2025-10-30 | 2025-09-30 | 0001104506-25-000053 | EDGAR | 36K words |
| 2025-08-07 | 2025-06-30 | 0001104506-25-000043 | EDGAR | 32K words |
| 2025-05-08 | 2025-03-31 | 0001104506-25-000026 | EDGAR | 28K words |
| 2024-10-31 | 2024-09-30 | 0001104506-24-000033 | EDGAR | 35K words |
| 2024-08-08 | 2024-06-30 | 0001104506-24-000026 | EDGAR | 34K words |
| 2024-05-09 | 2024-03-31 | 0001104506-24-000016 | EDGAR | 30K words |
| 2023-10-26 | 2023-09-30 | 0001104506-23-000025 | EDGAR | 36K words |
| 2023-08-03 | 2023-06-30 | 0001104506-23-000018 | EDGAR | 35K words |
| 2023-05-04 | 2023-03-31 | 0001104506-23-000012 | EDGAR | 31K words |
| 2022-10-27 | 2022-09-30 | 0001104506-22-000023 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001140361-26-031502 | EDGAR | 8K words |
| 2026-07-16 | 0001140361-26-028602 | EDGAR | 5K words |
| 2026-05-15 | 0001140361-26-021648 | EDGAR | 1K words |
| 2026-05-07 | 0001140361-26-019430 | EDGAR | 7K words |
| 2026-04-07 | 0001140361-26-013659 | EDGAR | 1K words |
| 2026-03-23 | 0001140361-26-010651 | EDGAR | 4K words |
| 2026-02-19 | 0001140361-26-006116 | EDGAR | 8K words |
| 2026-01-09 | 0001140361-26-000778 | EDGAR | 5K words |
| 2025-12-17 | 0001140361-25-045836 | EDGAR | 2K words |
| 2025-11-18 | 0001140361-25-042598 | EDGAR | 2K words |
208 total filings indexed. 176 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001104506 |
| Ticker | INSM |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | VA |
| Website | https://www.insmed.com |
| Listed | 2000-06-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INSM (~200 tokens, structured JSON with cryptographic provenance)